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Introduction and context {#s01}
========================

The cause of cerebral palsy (CP) is for the most part unknown. CP occurs in three to four infants per 1000 live births, resulting in 800,000 affected individuals in the US. Preterm birth is a major risk factor: 25% of CP cases occur in the 3.4% of infants born prior to 34 weeks' gestation. The lifetime economic cost for the care of patients with CP in the US born in 2000 was estimated to be \$11.5 billion (in 2003 dollars) \[[@bib-001]\].

The use of magnesium sulfate (MgSO~4~) for seizure prevention in patients with pre-eclampsia and later as a tocolytic agent in premature labor led to serendipitous observations suggesting that infants exposed to MgSO~4~ in late pregnancy were less likely to develop CP compared with infants born at similar gestational ages who were not exposed to MgSO~4~ \[[@bib-002]-[@bib-004]\]. In 1995, Nelson and Grether \[[@bib-005]\] published the first case-controlled study of the possible neuroprotective effect of MgSO~4~ on 42 infants (birth weight \<1500 g) with moderate or severe CP surviving to age 3 years compared to 75 control infants. The odds ratio for exposure to magnesium during the delivery admission was 0.14 (0.05-0.51). This effect persisted after control for other tocolytics, steroids, and the indication for MgSO~4~ treatment \[[@bib-005]\].

Recent advances {#s02}
===============

Subsequent to the study by Nelson and Grether, six other retrospective case-controlled studies were published \[[@bib-006]-[@bib-011]\], only one of which demonstrated a statistically significant reduction in neurological injury related to maternal MgSO~4~ treatment \[[@bib-009]\]. In addition, one of two retrospective cohort studies including a total of 2202 infants found a statistically significant reduction in the odds ratio for untoward neurological outcome \[[@bib-012],[@bib-013]\].

As a consequence of the favorable outcome in some of the retrospective studies, five randomized controlled trials were subsequently conducted to assess the hypothesis that antenatal MgSO~4~ reduces the risk of CP and mortality in preterm infants ([Table 1](#tbl-001){ref-type="table"}) \[[@bib-014]-[@bib-018]\]. Inclusion and exclusion criteria and dosage and timing of MgSO~4~ varied somewhat among the studies. Primary and secondary neonatal outcomes included, among other things, neonatal death and varying manifestations of neurological injury, including CP. Using endpoints of perinatal death or CP (to avoid the effect of bias as a result of neonatal death masking the risk of CP), some, though not all, of the five trials found a trend of reduced risk of death or CP, though in only one trial, albeit the largest of the five, was the reduction in the risk of CP statistically significant \[[@bib-018]\].

###### Randomized controlled trials: effect of magnesium sulfate treatment for expected premature birth on risk of perinatal death or cerebral palsy (CP)

![](medrep-02-78-t001)

  Study                                        Country; no. of location centers; no. of countries; no. of subjects   Inclusion                                    No. of infants     Regimen: initial dose; maintenance   CP RR (95% CI); combined perinatal death & CP RR (95% CI)
  -------------------------------------------- --------------------------------------------------------------------- -------------------------------------------- ------------------ ------------------------------------ --------------------------------------------------------------
  MagNET Mittendorf *et al*. \[[@bib-014]\]    US                                                                    25-33 weeks PTL                              165                4 g                                  Not significant (of n = 3 in both treated and placebo group)
  1                                            2-3 g/hr\*                                                                                                                                                                 
  1                                                                                                                                                                                                                       
  149                                          n/a                                                                                                                                                                        
  ACTOMgSO4 Crowther *et al*. \[[@bib-015]\]   Australia                                                             \<30 weeks                                   1255               4 g/20 mins                          0.85 (0.56-1.31)
  16                                           Delivery expected \<24 hrs                                            1 g/hr (not to exceed 24 hrs)                0.83 (0.66-1.03)                                        
  2                                                                                                                                                                                                                       
  1062                                                                                                                                                                                                                    
  Magpie Trial Duley *et al*.\[[@bib-016]\]    International                                                         \<37 weeks Severe pre-eclampsia              1593               4 g/10-15 mins                       0.66 (0.11-3.94)
  125                                          1 g/hr (for 24 hrs)                                                   1.06 (0.09-1.25)                                                                                     
  19                                                                                                                                                                                                                      
  1544                                                                                                                                                                                                                    
  PREMAG Marret *et al*.\[[@bib-017]\]         France                                                                \<33 weeks PTL                               688                4 g/30 mins                          0.70 (0.41-1.19)
  13                                           No maintenance                                                        0.86 (0.55-1.34)                                                                                     
  1                                                                                                                                                                                                                       
  573                                                                                                                                                                                                                     
  BEAM Rouse *et al*. \[[@bib-018]\]           US                                                                    24-31 weeks High risk of spontaneous birth   2444               6 g/20-30 mins                       0.59 (0.40-0.85)
  20                                           2 g/hr (for 12 hrs)                                                   0.97 (0.77-1.23)                                                                                     
  1                                                                                                                                                                                                                       
  2241                                                                                                                                                                                                                    

To avoid the problem of small sample size, there have been three meta-analyses using the data from the five randomized controlled trials \[[@bib-019]-[@bib-021]\]. These meta-analyses, which include a total of 5235 prospectively evaluated fetuses, benefit from being robust and homogeneous. The results of these three meta-analyses show convincingly that MgSO~4~ given to women at risk of premature birth significantly reduces the risk of CP by 30% without increasing the risk of perinatal or infant death. The meta-analyses confirm the results of the largest of the randomized controlled trials that assessed the neuroprotective benefit of MgSO~4~ \[[@bib-018]\]. Conde-Agudelo and Romero \[[@bib-020]\] calculated that to prevent 1 case of CP, 52 women at risk for preterm delivery at less than 34 weeks' of gestation would have to be treated with MgSO~4~. In another analysis, Constantine and Weiner \[[@bib-019]\] estimated that the number needed to treat at less than 32-40 weeks' gestation is 56 and at less than 30 weeks' gestation is 46.

Because of the varying dose and timing of MgSO~4~ in the randomized controlled trials, the ideal treatment regimen has not been established. Dosage in the trials varied from a loading dose of 4 g in 15 minutes to 6 g in 20 minutes, with maintenance infusion varying from none to 3 g per hour, and duration of infusion varying from 12 to 24 hours. These studies confirm that the protective effect of MgSO~4~ occurs when treatment is administered up to 34 weeks' gestation. Only one of the randomized controlled trials included patients randomized beyond 34 weeks' gestation \[[@bib-016]\]; consequently, the benefit of using MgSO~4~ beyond 34 weeks' gestation for its neuroprotective effect has not been established. Nor has the neuroprotective effect of MgSO~4~ been established for multiple gestations, but this may be due to the relatively few number of twin gestations that were included. In the largest trial, though not statistically significant, the risk reduction for twins was of the same magnitude as for singletons \[[@bib-018]\]. Other important clinical issues that were not addressed consistently in the randomized controlled trials include the use of MgSO~4~ in conjunction with tocolytic medications for preterm labor and retreatment regimens if delivery does not occur. Addressing the issue of retreatment, the protocol in the Beneficial Effects of Antenatal Magnesium Sulfate (BEAM) trial advised repeating the loading dose if at least 6 hours had passed since the discontinuation of the study medication \[[@bib-018]\]. It is important to emphasize that at low levels antenatal MgSO~4~ has beneficial neuroprotective effects and does not increase perinatal mortality or morbidity in very preterm infants \[[@bib-022]\].

The most common lesion associated with CP in infants born prematurely is periventricular white matter injury. The precise mechanism of action for the neuroprotective effect of MgSO~4~ in preterm infants is not known. Marret *et al*. \[[@bib-023]\] and Conde-Agudelo and Romero \[[@bib-020]\] have summarized the experimental evidence that supports several possible neuroprotective effects of magnesium. The ample biological rationale includes reduction of inflammatory cytokines or free radicals produced during hypoxic-ischemic reperfusion, prevention of excitotoxic calcium-induced injury, membrane stabilization that prevents the persistent membrane depolarization resulting from failure of the Na^+^-K^+^ ATP-dependent pump, inhibition of ionotropic glutamate receptors that are involved in injury to pre-oligodendrocytes, stabilization of rapid fluctuations in blood pressure that occur in neonates, and an increase in cerebral blood flow.

No maternal deaths and no life-threatening maternal side effects occurred in the five randomized controlled trials as a result of MgSO~4~ treatment \[[@bib-020]\]. Patients exposed to MgSO~4~ had a 50% increase of both hypotension and tachycardia compared with control patients. Also, an increased proportion of women receiving MgSO~4~ had a variety of side effects, including flushing, nausea or vomiting, and sweating, compared with control patients.

Implications for clinical practice {#s03}
==================================

MgSO~4~ should be considered for use in patients at high risk of delivery before 34 weeks' gestation, including during planned delivery, premature rupture of membranes, or active labor. Until further studies have determined a minimum effective dose and an optimum time to administer it, a reasonable regimen is a loading dose not exceeding 4 g, followed by a maintenance infusion of 1-2 g per hour for 24 hours.

Pending further information (secondary analysis of the prevention studies, animal data establishing an effective minimum dose, and so on), we believe a reasonable regimen to administer MgSO~4~ for neuroprotection includes a 4 g bolus, 1 g per hour maintenance infusion, and re-bolus if the MgSO~4~ has not been administered for more than 6 hours. Given that it takes around 4 hours for MgSO~4~ levels to reach a steady state in the fetus, we attempt to begin the infusion at least 4 hours prior to birth if possible, but would give it as late as 1 hour prior to birth. The MgSO~4~ can be discontinued after 12 hours if preterm birth no longer appears imminent. MgSO~4~ should not be given concurrently with calcium channel blockers. We recommend that, if possible, MgSO~4~ infusion be postponed for 3-4 hours after the last dose of a calcium channel blocker such as nifedipine. However, if continued tocolysis is deemed necessary, depending on the clinical circumstances, indomethacin might be preferable to a calcium channel blocker.
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